MKP10241

MKP10241 is an orally active GPR119 agonist. MKP10241 elevates cAMP levels in the GPR119 expressing cell line (EC50: 3.7 nM) . MKP10241 reduces blood glucose levels and HbA1c in acute models and a chronic diabetic mouse model. MKP10241 also demonstrates excellent preclinical efficacy in acute as well as chronic rodent models of obesity, and MASH[1].

Product Specifications

CAS Number

[2137977-29-6]

UNSPSC

12352005

Target

GPR119

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Metabolic Disease

Smiles

C[C@@H](C1CCN(CC1)C2=NC=C(C=N2)CC)OC(S3)=NN4C3=NC(C5=CC=C(C=C5F)S(C)(=O)=O)=C4

Molecular Formula

C24H27FN6O3S2

Molecular Weight

530.64

References & Citations

[1]Rai SK, et al. Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders. J Med Chem. 2025 Oct 7.